Agilent Technologies Advances Chromatography Innovations for Pharma and Biotech Efficiency in 2026
Published: 31 Mar 2026
Author: Precedence Research
Agilent, with the help of expertise, advanced and compliance-enabled technologies, and manufacturing capabilities, which include system, software, and consumables, offers services like contract development. Chromatography solutions enhance precision and speed in the drug discovery workflow, which helps to reduce cost, consumption, and carbon footprint to help meet the organisation’s sustainability objectives. These developments support countries like Europe in the pharmaceutical sector.
For DACH investor this will be a slow and steady evolution that provides diversification opportunities as European regulatory standards and biotech intensify. These innovations reduce processing time by 30% while delivering ultra-high resolution for complex biomolecule separation, which show critical need in drug development and rising demand for analytical tools.
According to Towards Healthcare, the Chromatography in Biotechnology market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 12.85 billion in 2026 to approximately USD 27.68 billion by 2035, representing a compound annual growth rate (CAGR) of 8.9% from 2026 to 2035. The growth of the Chromatography in Biotechnology Market is driven by increasing biopharmaceutical production, rising demand for purification techniques, advancements in chromatography technologies, expanding research activities, stringent regulatory requirements, and growing adoption of biologics and personalized medicine worldwide across global sectors.
Technical Enhancements Powering Precision
InfinityLab LC series with Quaternary Pumps provides flexibility for solvents of complex gradients, often offering binary-like mixing performance for higher precision. This ensures consistent results even in high-throughput environments.
Sensitivity improvement enables food safety testing by porous layer open tubular columns, with lower detection limits for trace volatiles.
The advancement of the Maxlight detector in UHPLC modes offers a resolution 50% higher than competitors have the capacity to capture, allowing for fine separation details critical for isomer differentiation, which is particularly valuable in synthetic chemical validation. This enhances the precision and the speed of the drug discovery workflow. This gave rise to the demand for an analytical tool in the pharmaceutical sector.
Recent Developments in Agilent's Chromatography Portfolio
Peptide mapping and glycan analysis are essential for the characterisation and quality control of next-generation therapeutics which monoclonal antibodies and cell therapies.
Laboratories have improved sensitivity for impurity detection and also introduced a threshold essential for regulatory compliance in drug quality control. These capabilities directly support the pipeline acceleration seen in global pharma R&D.
A recent report by Towards Healthcare highlights that the Chromatography in Biotechnology market, driven by increasing biologics production, technological advancements, and rising research investments, is expected to witness robust growth with expanding applications across drug development, diagnostics, and bioprocessing industries globally.